Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Denton

Showing results (11-20 of 607) with videos related to

Pageof 61
Sort By:
Home Care Provider|August 1, 1997
Do I need a flu shot?A P Denton
Clinical and Experimental Rheumatology|October 13, 2015
Systemic sclerosis: from pathogenesis to targeted therapyChristopher P Denton
Clinical Medicine (London, England)|February 3, 2016
Advances in pathogenesis and treatment of systemic sclerosisChristopher P Denton
Clinical Medicine (London, England)|December 5, 2015
Advances in pathogenesis and treatment of systemic sclerosisChristopher P Denton
Methods in Molecular Biology (Clifton, N.J.)|February 17, 1998
Leucine incorporation and thymidine incorporationC P Denton
Arthritis Research & Therapy|September 15, 2007
Therapeutic targets in systemic sclerosisChristopher P Denton
The Lancet. Respiratory Medicine|July 30, 2016
Scleroderma Lung Study II-clarity or obfuscation?Christopher P Denton
Seminars in Arthritis and Rheumatism|November 30, 2019
Challenges in systemic sclerosis trial designChristopher P Denton
Rheumatology (Oxford, England)|December 10, 2024
Comment on: The 2024 British Society for Rheumatology guideline for management of systemic sclerosis. ReplyChristopher P Denton,
Journal of Scleroderma and Related Disorders|April 6, 2022
Systemic sclerosis phase III clinical trials: Hope on the horizon?Martin Aringer, Christopher P Denton
Pageof 61

Showing results (11-20 of 607) with videos related to

Sort By:
Pageof 61
Home Care Provider|August 1, 1997
Do I need a flu shot?A P Denton
Clinical and Experimental Rheumatology|October 13, 2015
Systemic sclerosis: from pathogenesis to targeted therapyChristopher P Denton
Clinical Medicine (London, England)|February 3, 2016
Advances in pathogenesis and treatment of systemic sclerosisChristopher P Denton
Clinical Medicine (London, England)|December 5, 2015
Advances in pathogenesis and treatment of systemic sclerosisChristopher P Denton
Methods in Molecular Biology (Clifton, N.J.)|February 17, 1998
Leucine incorporation and thymidine incorporationC P Denton
Arthritis Research & Therapy|September 15, 2007
Therapeutic targets in systemic sclerosisChristopher P Denton
The Lancet. Respiratory Medicine|July 30, 2016
Scleroderma Lung Study II-clarity or obfuscation?Christopher P Denton
Seminars in Arthritis and Rheumatism|November 30, 2019
Challenges in systemic sclerosis trial designChristopher P Denton
Rheumatology (Oxford, England)|December 10, 2024
Comment on: The 2024 British Society for Rheumatology guideline for management of systemic sclerosis. ReplyChristopher P Denton,
Journal of Scleroderma and Related Disorders|April 6, 2022
Systemic sclerosis phase III clinical trials: Hope on the horizon?Martin Aringer, Christopher P Denton
Pageof 61